MoherDSchulzKFAltmanDG. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Clin Oral Investig2003;7:2–7.
2.
KassirerJPCampionEW. Peer review. Crude and understudied, but indispensable. JAMA1994;272:96–7.
3.
ManganoDTTudorICDietzelC. The risk associated with aprotinin in cardiac surgery. N Engl J Med2006;354:353–65.
4.
SedrakyanATreasureTElefteriadesJA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: A systematic review and meta-analysis of randomized clinical trials [Review]. J Thorac Cardiovasc Surg2004;128:442–8.
5.
HenryDAMoxeyAJCarlessPAO'ConnellDMcClellandBHendersonKM. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion [Review]. Cochrane Database Syst Rev2001;1:CD001886.
6.
ManganoDT. Aspirin and mortality from coronary bypass surgery. N Engl J Med2002;347:1309–17.
7.
ManganoCMDiamondstoneLSRamsayJGAggarwalAHerskowitzAManganoDT. Renal dysfunction after myocardial revascularization: Risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Ann Intern Med1998;128:194–203.
8.
AltmanDG. Poor-quality medical research: What can journals do?JAMA2002;287:2765–7.